Company: SNPS
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0000883241-25-000017
Chunk: 39

Company: SYNOPSYS INC
Filing Date: 2025-05-28
Form: 10-Q
Item: Item 1
Chunk 39
---
37,412)52,612 Unrealized loss on settlement of interest rate treasury lock(121,643)— Net cash provided by operating activities207,910 388,800 Cash flows from investing activities:Proceeds from maturities of short-term investments35,461 63,159 Proceeds from sales of short-term investments22,015 — Purchases of short-term investments(47,558)(65,861)Proceeds from sales of strategic investments— 55,696 Purchases of strategic investments(3,368)(860)Purchases of property and equipment, net(96,303)(78,763)Proceeds from sale of building74,279 — Acquisitions, net of cash acquired— (139,557)Proceeds from business divestiture, net of cash divested70,082 — Other(611)— Net cash provided by (used in) investing activities53,997 (166,186)Cash flows from financing activities:Proceeds from debt, net of issuance costs10,034,464 — Repayment of debt (1,289)(1,303)Payment of bridge financing and term loan costs— (54,715)Issuances of common stock118,308 115,111 Payments for taxes related to net share settlement of equity awards(166,872)(212,577)Redemption of redeemable non-controlling interest(30,000)— Other— (1,096)Net cash provided by (used in) financing activities9,954,611 (154,580)Effect of exchange rate changes on cash, cash equivalents and restricted cash8,186 2,423 Net change in cash, cash equivalents and restricted cash 10,224,704 70,457 

6

Cash, cash equivalents and restricted cash, beginning of year, including cash from discontinued operations3,898,729 1,441,187 Cash, cash equivalents and restricted cash, end of period, including cash from discontinued operations 14,123,433 1,511,644 Less: Cash, cash equivalents and restricted cash from discontinued operations— 6,445 Cash, cash equivalents and restricted cash from continuing operations$14,123,433 $1,505,199 

See the accompanying Notes to Condensed Consolidated Financial Statements (unaudited).

7

SYNOPSYS, INC.

NOTES TO CONDENSED CONS